RxDoctor Payments Data

Shone Almeida, MD

Cardiovascular Disease · Tampa, FLNPI 1225303563

Payments from drug & device makers

$138,496in general payments, 2019–2025

Across 144 payments — averaging $961.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$58K
  • Novartis$53K
  • Cleerly, Inc.$25K
  • Canon Medical Informatics, Inc.$1K
  • Amgen$779
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$256
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$3,16310%
  • Speaking & faculty fees$22,73474%
  • Travel & lodging$1,3294%
  • Food & beverage$3,50511%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,496 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$98,660
Medicare patients
835
Services billed
2,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab65$48,789
EntrestoSacubitril/Valsartan30$41,577
EliquisApixaban38$39,484
OzempicSemaglutide27$23,217
Praluent PenAlirocumab21$19,078
Repatha PushtronexEvolocumab13$7,315
Rosuvastatin Calcium64$752
Metoprolol Succinate105$725
Atorvastatin Calcium106$460
Ezetimibe35$442
ClopidogrelClopidogrel Bisulfate33$301
Losartan Potassium87$273
Isosorbide Mononitrate ErIsosorbide Mononitrate25$205
Amlodipine Besylate30$135
Carvedilol40$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$52,968$41,57730 claims
PfizerEliquis$157$39,48438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →